Tier 2 — strong

Soothing and anti-itch effect of quercetin phytosome in human subjects: a single-blind study

Giada Maramaldi, Stefano Togni, Ivan Pagin, Luca Giacomelli, Roberta Cattaneo, Roberto Eggenhöffner, Samuele E Burastero
Clinical, cosmetic and investigational dermatology 2016 9:55

Bibliography

PubMed
PMID 27013898
PubMed Central
PMC4777224
DOI
10.2147/CCID.S98890
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignSingle-blind controlled topical challenge study
ModelHuman intervention research
Sample30 healthy volunteers
InterventionQuercetin-phospholipid 1% cream, placebo, untreated skin, and topical dexchlorpheniramine
DurationAcute controlled skin-irritation challenges
EndpointsSymptoms and quality of life

What the study showed, in plain terms

Published in 2016, this source examined skin and topical formulations. Design: Single-blind controlled topical challenge study. Sample/model: 30 healthy volunteers. The exposure or intervention was Quercetin-phospholipid 1% cream, placebo, untreated skin, and topical dexchlorpheniramine. Follow-up or treatment period: Acute controlled skin-irritation challenges.

The quercetin cream reduced selected erythema and wheal measures after experimental irritation.

Small local challenge study of a specific topical product. It does not establish efficacy of oral supplements, long-term eczema control, or equivalence in clinical allergy treatment.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Skin and Hair: Oral vs Topical Evidence. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • The quercetin cream reduced selected erythema and wheal measures after experimental irritation.
  • The recorded outcome domains were Symptoms and quality of life.
  • The result applies to the tested exposure: Quercetin-phospholipid 1% cream, placebo, untreated skin, and topical dexchlorpheniramine; Acute controlled skin-irritation challenges.

What this study can and cannot tell us

  • Small local challenge study of a specific topical product. It does not establish efficacy of oral supplements, long-term eczema control, or equivalence in clinical allergy treatment.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Comparative evaluation of the effect of permeation enhancers, lipid nanoparticles and colloidal silica on in vivo human skin penetration of quercetin
S Scalia et al. · Skin pharmacology and physiology · 2013
Tier 2
Management of aphthous ulceration with topical quercetin: a randomized clinical trial
Ahmed Abd El-Meguid Mostafa Hamdy et al. · The journal of contemporary dental practice · 2010

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology